In principle, it will be possible to prevent ATP release into the TME, thus reducing P2 receptor stimulation and adenosine generation, or target selected receptors (i.e., P2X7R or A2A) on the host or on the tumor cells. Here, IGKV2D-29 is linked to neoplasm.